Debiopharm Group

Debiopharm Group’s antibiotic Debio 1450 receives QIDP designation from the FDA

Friday, September 5, 2014

Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including anti-infective and oncology therapeutics as well as companion diagnostics, has announced that the FDA has designated its anti-infectious agent Debio 1450 as a Qualified Infectious Disease Product (QIDP) for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

[Read More]

Debiopharm, Nobelex Biotech collaborate

Thursday, June 26, 2014

Debiopharm Group, a Switzerland-based global biopharmaceutical company developing prescription drugs that target unmet medical needs including anti-infective and oncology therapeutics as well as companion diagnostics, and Nobelex Biotech, a Canadian company focusing on the discovery and early development of novel antimicrobial drugs, are collaborating on two discovery programs to develop antibiotics targeting Neisseria gonorrhoeae and enteric species utilizing a novel mechanism of action.

[Read More]

Debiopharm Group initiates phase I study of Debio 1450 for staphylococcal infections

Thursday, June 19, 2014

Debiopharm Group, a Swiss-based global biopharmaceutical company developing prescription drugs that target unmet medical needs as well as companion diagnostics, has launched a phase I dose-escalation study of Debio 1450 (previously known as AFN-1720), a highly potent anti-infective agent that is selectively active against a large number of Staphylococcus species, including all known resistant strains such as methicillin-resistant S. aureus (MRSA) and vancomycin-intermediate S. aureus (VISA).

[Read More]

Evotec, Debiopharm Group to collaborate on new treatment for cancer

Thursday, April 3, 2014

Evotec has formed a research collaboration and licensing deal with Debiopharm Group, a Swiss-based global biopharmaceutical group, to identify and develop novel compounds having the potential to treat multiple forms of solid tumors and leukemia’s with defined genetic alterations. Discovery and preclinical development efforts will be driven by Evotec, while Debiopharm will manage clinical development. Evotec will receive R&D funding and high double-digit total payments triggered by clinical, regulatory and commercial milestones, plus royalties on sales of resulting commercial products.

[Read More]

Cenix BioScience, Debiopharm Group to identify predictive biomarkers

Wednesday, May 29, 2013

Cenix BioScience, a preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven pharmacology, and Debiopharm Group, a global Swiss biopharmaceutical group of companies focused on prescription drugs that target unmet medical needs, including oncology and companion diagnostics, have signed a research agreement to support Debiopharm in its ongoing efforts to develop novel therapeutic drug candidates.

[Read More]